HAEMONETICS CORP/MASS (HAE) Stock Fundamental Analysis
USA - NYSE:HAE - US4050241003 - Common Stock
68.36 USD
+1.25 (+1.86%)
68.36 USD
0 (0%)
HAE gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. While HAE has a great profitability rating, there are some minor concerns on its financial health. HAE scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
HAE had positive earnings in the past year.
In the past year HAE had a positive cash flow from operations.
Each year in the past 5 years HAE has been profitable.
In the past 5 years HAE always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of HAE (6.63%) is better than 87.30% of its industry peers.
HAE's Return On Equity of 18.51% is amongst the best of the industry. HAE outperforms 93.12% of its industry peers.
HAE has a better Return On Invested Capital (9.88%) than 89.42% of its industry peers.
HAE had an Average Return On Invested Capital over the past 3 years of 8.96%. This is in line with the industry average of 9.12%.
The last Return On Invested Capital (9.88%) for HAE is above the 3 year average (8.96%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.63% | ||
| ROE | 18.51% | ||
| ROIC | 9.88% |
ROA(3y)6.05%
ROA(5y)4.97%
ROE(3y)15.59%
ROE(5y)12.69%
ROIC(3y)8.96%
ROIC(5y)7.22%
1.3 Margins
HAE has a Profit Margin of 12.13%. This is amongst the best in the industry. HAE outperforms 88.89% of its industry peers.
In the last couple of years the Profit Margin of HAE has grown nicely.
With an excellent Operating Margin value of 18.12%, HAE belongs to the best of the industry, outperforming 88.36% of the companies in the same industry.
In the last couple of years the Operating Margin of HAE has remained more or less at the same level.
HAE has a Gross Margin (57.42%) which is in line with its industry peers.
In the last couple of years the Gross Margin of HAE has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.12% | ||
| PM (TTM) | 12.13% | ||
| GM | 57.42% |
OM growth 3Y21.18%
OM growth 5Y0.48%
PM growth 3Y41.28%
PM growth 5Y9.75%
GM growth 3Y1.97%
GM growth 5Y2.6%
2. Health
2.1 Basic Checks
HAE has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for HAE has been reduced compared to 1 year ago.
The number of shares outstanding for HAE has been reduced compared to 5 years ago.
HAE has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.49 indicates that HAE is not a great score, but indicates only limited risk for bankruptcy at the moment.
HAE has a better Altman-Z score (2.49) than 66.14% of its industry peers.
The Debt to FCF ratio of HAE is 7.62, which is on the high side as it means it would take HAE, 7.62 years of fcf income to pay off all of its debts.
HAE has a better Debt to FCF ratio (7.62) than 75.13% of its industry peers.
HAE has a Debt/Equity ratio of 1.04. This is a high value indicating a heavy dependency on external financing.
HAE has a worse Debt to Equity ratio (1.04) than 77.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.04 | ||
| Debt/FCF | 7.62 | ||
| Altman-Z | 2.49 |
ROIC/WACC1.41
WACC6.99%
2.3 Liquidity
A Current Ratio of 1.72 indicates that HAE should not have too much problems paying its short term obligations.
HAE's Current ratio of 1.72 is on the low side compared to the rest of the industry. HAE is outperformed by 69.84% of its industry peers.
HAE has a Quick Ratio of 1.04. This is a normal value and indicates that HAE is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.04, HAE is not doing good in the industry: 75.66% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.04 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 17.65% over the past year.
Measured over the past 5 years, HAE shows a small growth in Earnings Per Share. The EPS has been growing by 6.66% on average per year.
Looking at the last year, HAE shows a small growth in Revenue. The Revenue has grown by 3.95% in the last year.
The Revenue has been growing slightly by 6.60% on average over the past years.
EPS 1Y (TTM)17.65%
EPS 3Y20.84%
EPS 5Y6.66%
EPS Q2Q%13.39%
Revenue 1Y (TTM)3.95%
Revenue growth 3Y11.07%
Revenue growth 5Y6.6%
Sales Q2Q%-5.26%
3.2 Future
HAE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.37% yearly.
Based on estimates for the next years, HAE will show a small growth in Revenue. The Revenue will grow by 2.79% on average per year.
EPS Next Y6.66%
EPS Next 2Y9.85%
EPS Next 3Y10.37%
EPS Next 5YN/A
Revenue Next Year-4.81%
Revenue Next 2Y0.62%
Revenue Next 3Y2.79%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
HAE is valuated correctly with a Price/Earnings ratio of 14.24.
HAE's Price/Earnings ratio is rather cheap when compared to the industry. HAE is cheaper than 86.24% of the companies in the same industry.
When comparing the Price/Earnings ratio of HAE to the average of the S&P500 Index (25.83), we can say HAE is valued slightly cheaper.
With a Price/Forward Earnings ratio of 12.40, HAE is valued correctly.
HAE's Price/Forward Earnings ratio is rather cheap when compared to the industry. HAE is cheaper than 88.89% of the companies in the same industry.
HAE is valuated cheaply when we compare the Price/Forward Earnings ratio to 32.68, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.24 | ||
| Fwd PE | 12.4 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HAE is valued cheaper than 85.19% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, HAE is valued cheaper than 85.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.48 | ||
| EV/EBITDA | 11.6 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates HAE does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of HAE may justify a higher PE ratio.
PEG (NY)2.14
PEG (5Y)2.14
EPS Next 2Y9.85%
EPS Next 3Y10.37%
5. Dividend
5.1 Amount
HAE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
68.36
+1.25 (+1.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners115.71%
Inst Owner Change0.1%
Ins Owners1.14%
Ins Owner Change9.07%
Market Cap3.29B
Revenue(TTM)1.36B
Net Income(TTM)163.34M
Analysts81.33
Price Target79.25 (15.93%)
Short Float %7.01%
Short Ratio3.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.91%
Min EPS beat(2)0.62%
Max EPS beat(2)7.2%
EPS beat(4)4
Avg EPS beat(4)2.96%
Min EPS beat(4)0.62%
Max EPS beat(4)7.2%
EPS beat(8)7
Avg EPS beat(8)4%
EPS beat(12)11
Avg EPS beat(12)9.1%
EPS beat(16)14
Avg EPS beat(16)8.76%
Revenue beat(2)1
Avg Revenue beat(2)1.96%
Min Revenue beat(2)-0.63%
Max Revenue beat(2)4.55%
Revenue beat(4)1
Avg Revenue beat(4)0.38%
Min Revenue beat(4)-2.22%
Max Revenue beat(4)4.55%
Revenue beat(8)4
Avg Revenue beat(8)1.08%
Revenue beat(12)8
Avg Revenue beat(12)2.33%
Revenue beat(16)10
Avg Revenue beat(16)1.82%
PT rev (1m)-3.24%
PT rev (3m)-16.63%
EPS NQ rev (1m)0.25%
EPS NQ rev (3m)-5.3%
EPS NY rev (1m)0.01%
EPS NY rev (3m)-0.82%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)-3.21%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-1.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.24 | ||
| Fwd PE | 12.4 | ||
| P/S | 2.45 | ||
| P/FCF | 20.48 | ||
| P/OCF | 14.54 | ||
| P/B | 3.73 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.6 |
EPS(TTM)4.8
EY7.02%
EPS(NY)5.52
Fwd EY8.07%
FCF(TTM)3.34
FCFY4.88%
OCF(TTM)4.7
OCFY6.88%
SpS27.94
BVpS18.31
TBVpS-3.65
PEG (NY)2.14
PEG (5Y)2.14
Graham Number44.47
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.63% | ||
| ROE | 18.51% | ||
| ROCE | 12.63% | ||
| ROIC | 9.88% | ||
| ROICexc | 11.65% | ||
| ROICexgc | 32.9% | ||
| OM | 18.12% | ||
| PM (TTM) | 12.13% | ||
| GM | 57.42% | ||
| FCFM | 11.95% |
ROA(3y)6.05%
ROA(5y)4.97%
ROE(3y)15.59%
ROE(5y)12.69%
ROIC(3y)8.96%
ROIC(5y)7.22%
ROICexc(3y)10.46%
ROICexc(5y)8.47%
ROICexgc(3y)26.78%
ROICexgc(5y)22.33%
ROCE(3y)11.45%
ROCE(5y)9.23%
ROICexgc growth 3Y22.36%
ROICexgc growth 5Y7.33%
ROICexc growth 3Y21.7%
ROICexc growth 5Y-5.09%
OM growth 3Y21.18%
OM growth 5Y0.48%
PM growth 3Y41.28%
PM growth 5Y9.75%
GM growth 3Y1.97%
GM growth 5Y2.6%
F-Score8
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.04 | ||
| Debt/FCF | 7.62 | ||
| Debt/EBITDA | 2.56 | ||
| Cap/Depr | 57.06% | ||
| Cap/Sales | 4.88% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 63.09% | ||
| Profit Quality | 98.45% | ||
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.04 | ||
| Altman-Z | 2.49 |
F-Score8
WACC6.99%
ROIC/WACC1.41
Cap/Depr(3y)79.52%
Cap/Depr(5y)76.24%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.58%
Profit Quality(3y)103.91%
Profit Quality(5y)115.34%
High Growth Momentum
Growth
EPS 1Y (TTM)17.65%
EPS 3Y20.84%
EPS 5Y6.66%
EPS Q2Q%13.39%
EPS Next Y6.66%
EPS Next 2Y9.85%
EPS Next 3Y10.37%
EPS Next 5YN/A
Revenue 1Y (TTM)3.95%
Revenue growth 3Y11.07%
Revenue growth 5Y6.6%
Sales Q2Q%-5.26%
Revenue Next Year-4.81%
Revenue Next 2Y0.62%
Revenue Next 3Y2.79%
Revenue Next 5YN/A
EBIT growth 1Y18.51%
EBIT growth 3Y34.59%
EBIT growth 5Y7.12%
EBIT Next Year30.67%
EBIT Next 3Y15.4%
EBIT Next 5YN/A
FCF growth 1Y-8.53%
FCF growth 3Y16.98%
FCF growth 5Y2.09%
OCF growth 1Y-9.46%
OCF growth 3Y1.79%
OCF growth 5Y2.81%
HAEMONETICS CORP/MASS / HAE FAQ
What is the ChartMill fundamental rating of HAEMONETICS CORP/MASS (HAE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to HAE.
What is the valuation status for HAE stock?
ChartMill assigns a valuation rating of 7 / 10 to HAEMONETICS CORP/MASS (HAE). This can be considered as Undervalued.
How profitable is HAEMONETICS CORP/MASS (HAE) stock?
HAEMONETICS CORP/MASS (HAE) has a profitability rating of 8 / 10.
What are the PE and PB ratios of HAEMONETICS CORP/MASS (HAE) stock?
The Price/Earnings (PE) ratio for HAEMONETICS CORP/MASS (HAE) is 14.24 and the Price/Book (PB) ratio is 3.73.